Top View
- ZEPHYR: Failure of a “Spring Wind” in Lung Cancer
- Tyrosine Kinase Inhibitors (Tkis) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
- Afatinib: Drug Information
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Optimal Alternative Therapy for Metastatic HER2- Positive Breast
- Supplementary Appendix
- 201292Orig1s000
- Giotrif, INN-Afatinib
- Afatinib Monograph
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models Catherine A
- Second-Line Treatment for Advanced NSCLC Without Actionable Mutations: Is Immunotherapy the ‘Panacea’ for All Patients? Alessandro Morabito
- Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer
- Cardiac Safety of Afatinib: a Review of Data from Clinical Trials Michael S
- Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, Pnaclamp, and Digital PCR
- A Comparison Between First-, Second- and Third-Generation Epidermal
- Proton Pump Inhibitors and Oncologic Treatment Efficacy
- Exploring the Expansion of the Medicines Patent Pool's Mandate To
- Afatinib Is a New Therapeutic Approach in Chordoma with A
- Original Article Clinical Observations of Sunitinib Combined with Docetaxel for Advanced Non-Small Cell Lung Cancer and Its Effects on Serum IL-6 and TNF-Α
- Targeting Mutant RAS in Patient-Derived Colorectal Cancer Organoids by Combinatorial
- Versus Single-Agent HER2 Inhibition and Incidence of Intracranial
- Early Clinical Development of Targeted Anticancer Agents
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine
- Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
- Efficacy of Combination Treatment Using YHO-1701, an Orally Active
- Overcoming EGFR Bypass Signal-Induced Acquired
- Novel Receptor Tyrosine Kinase Targeted Combination Therapies for Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST)
- Afatinib and Gefitinib: a Direct Comparison
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
- Maryland Medicaid Pharmacy Program Quantity Limits
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
- Brain Distribution of a Panel of EGFR Inhibitors Using Cassette-Dosing in Wild-Type and Abcb1/Abcg2 Deficient Mice
- Progress in Anti-HER2 Targeted Therapy of Metastatic Lung Cancer
- Cell Line Panel Profiling Reveals That MEK Inhibitors
- EGFR IHC >0 (95,2%) As a Biomarker
- The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: a Multicenter Observational Study
- Treating Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors: Still a Work in Progress
- Therascreen EGFR RGQ PCR Kit US Instructions For